Bayer announced today that new research findings on Xofigo ® (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical ...

New data from the Phase III PEACE III trial showed that XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly improved prostate-specific antigen (PSA) response rates (≥90% at ...

Researchers at the University of Sheffield have received new funding to investigate if radium-223 (Ra-223), currently used to treat bone metastases in prostate cancer, might also help in bone spread ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases. Radium-223 (Xofigo) produced ...

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy. Treatment with radium-223 was safe ...

Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors Patients with bone metastatic CRPC ...

This week, the FDA approved radium-223 injection for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. It is the first FDA-approved alpha particle-emitting ...

Retrospective study to evaluate prostate cancer screening in a resident practice at a major teaching hospital. Background: Radium-223 chloride (Alpharadin) is a first-in-class targeted ...

According to an expert from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, radium-223 shows positive efficacy and safety findings for patients with metastatic castration-resistant prostate ...